Texas Oncology-Dallas

Dallas, Texas 75251

3 studies enrolling now · 11 studies all time

What they study most

Advanced Solid Tumor, Cancer, ER Positive, Her2 Negative Breast Cancer Patients, Endometrial Cancer, Gastric Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Gastroesophageal Junction Adenocarcinoma, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma

Studies at this site

• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Recruiting now
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting now
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers — Recruiting now
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Running, not enrolling
• Development and Validation of Harbinger Health Test for Early Cancer Detection — Completed
• A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer — Stopped early
• CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) — Completed
• A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection — Stopped early
• A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer — Completed